A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy (SPOTLIGHT)
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Fluorine 18 flotufolastat (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms SPOTLIGHT
- Sponsors Blue Earth Diagnostics
- 29 May 2024 According to Blue Earth Diagnostics media release, data from this study will be presented in upcoming presentations by its collaborators at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 8 to 11, 2024, in Toronto, Canada.
- 08 May 2024 According to a Blue Earth Diagnostics media release, company plan to make analytical data from the Phase 3 SPOTLIGHT trial of POSLUMA available in the future.
- 27 Jan 2024 Results assessing the impact of 18F-flotufolastat on planned treatment after curative-intent primary therapy presented at the 2024 Genitourinary Cancers Symposium.